Eris Lifesciences Ltd · NSE:ERIS
Eris Lifesciences — Investor Presentation (October 2021)
30 slides from Eris Lifesciences's investor presentation, Oct 30, 2021
Slide 1: Exchange intimation: Corporate Presentation
Date: 30th October, 2021 To To BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza Dalal Street Bandra Kurla Complex Mumbai- 400001 Bandra (E) Mumbai-400051 Security Code: 540596 Symbol: ERIS SUBJECT: CORPORATE PRESENTATION Dear Sir/Madam, Pursuant to the re
Slide 2: Eris Lifesciences Corporate Presentation November 2021
Eris Lifesciences Corporate Presentation November 2021
Slide 3: Business Highlights
Business Highlights § Only Indian listed pharmaco with a pure-play Revenues up 2x and PAT up 2.6x in last 5 years Domestic Branded Formulations model Revenue PAT § Youngest among India’s Top-25 domestic branded formulation pharmacos 12,119 § Chronic and Sub-Chronic therapies account for 5,970 92% of
Slide 4: Financial Snapshot
Financial Snapshot FY 21 H1 FY 22 ₹ mn ₹ mn ₹ mn ₹ mn 12,119 4,306 7,089 2,663 Op Revenue 12.8% EBITDA 16.9% Op Revenue 13.8% EBITDA 16.4% yoy growth yoy growth yoy growth yoy growth ₹ mn ₹ mn ₹ 3,551 26.16 2,251 PAT 19.8% EPS 21.0% PAT 14.4% yoy growth yoy growth yoy growth Dividends as % of net pr
Slide 5: Eris has Maintained Market-Leading Growth from Pre-Covid Levels
Eris has Maintained Market-Leading Growth from Pre-Covid Levels Eris has outperformed the 21.2% IPM by 390 bps p.a. 19.0% since pre-Covid times 16.3% 14.9% 13.5% 12.6% 12.2% 11.6% 10.5% 10.4% 8.3% IPM exl. IPCA ARISTO MACLEODS MANKIND EMCURE TOR RENT ERIS LS INTAS ALEMBIC CIPLA Covid molecules % Acu
Slide 6: Chronic and Sub-Chronic focus with outperformance in Core Areas
Chronic and Sub-Chronic focus with outperformance in Core Areas § An India-focused branded formulations business with 92% revenues Outperformance in Core therapies from Pre-Covid levels from Chronic and Sub-chronic therapies, primarily Oral Diabetes Oral anti-diabetes Cardiovascular Care, Cardiac Ca
Slide 7: Top-15 Power Brands Portfolio Contributes ~75% of Revenue
Top-15 Power Brands Portfolio Contributes ~ 75% of Revenue Our Top 15 Mother Brands contribute ~ 75% of our revenue Blockbuster additions to power brand portfolio in the last two years MAT Sep’21 Sales (₹ mn) Market share ` 2,813 6% 1,426 4% • Crossed INR 54+ crore of annual revenue 1,387 8% • Rank
Slide 8: Eris Enjoys High Prescription Ranks among Super-Specialists
Eris Enjoys High Prescription Ranks among Super-Specialists Eris Prescription Ranks* among leading Doctor Specialties 3 4 3 DIABETOLOGISTS CARDIOLOGISTS NEUROLOGISTS 4 6 CONSULTING GASTROENTEROLOGISTS PHYSICIANS 7 Source: SMSRC MAT Aug 2021 │ │ * In the represented market
Slide 9: Eris Enjoys a Strong Position in the ~INR 9,000 Crore Oral Anti-Diabetes Market
Eris Enjoys a Strong Position in the ~ INR 9,000 Crore Oral Anti-Diabetes Market Eris has built a full-service presence in Oral Anti-Diabetes Eris ranks in Oral Anti-Diabetes therapy therapy with high market ranks in latest generation molecules (DPP4 and SGLT2 inhibitors) By Revenue* Total # Rx** Rx
Slide 10: Eris Continues to Create Value from Acquisitions
Eris Continues to Create Value from Acquisitions Indian Branded Formulation Business of Strides Shasun (2017) Zomelis (2019) § Discontinued tail-end brands; focused attention on Top- § Consistently ranked #1 among all (95+) Gx versions of 5 brands in the portfolio (Renerve, Raricap, Ginkocer, Vildag
Slide 11: Three Pillars of Our Market Engagement
Three Pillars of Our Market Engagement The core focus of our market engagement is to enable clinicians to improve clinical outcomes in patients through timely and precision diagnosis and treatment 1 2 3 Dissemination of Generation of Patient Care initiatives latest scientific actionable scientific f
Slide 12: Leading the Digital Dissemination of Scientific Knowledge
1. Leading the Digital Dissemination of Scientific Knowledge since the Start of the Pandemic • As a prominent stakeholder in the enhancement of scientific knowledge, Eris has conducted ~3,200+ digital (group) interactions since the start of the pandemic covering 46,000+ doctors • Discussion topics i
Slide 13: Pioneering India-Centric Studies – The India Heart Study
2. Pioneering India-Centric Studies to Generate Actionable Scientific Evidence – The India Heart Study IHS Methodology IHS Revealed Expert Speak The investigators examined the blood 42% of the participants were White-coat hypertensives get pressure of 18,918 participants with misdiagnosed and were u
Slide 14: Patient Care – Driving Precision Diagnosis and Better Disease Management
3. Patient Care – Driving Precision Diagnosis and Better Disease Management § Our Patient Care Initiatives (PCI) platform enables us to bring cutting- edge healthcare solutions to our patients through the involvement and cooperation of Key Opinion Leaders Number of Patients Screened Number of Patien
Slide 15: Our Manufacturing Infrastructure
Our Manufacturing Infrastructure WHO-GMP manufacturing 74% of revenue (in FY21) and WHO GMP facility in Guwahati, Assam facility in Guwahati, Assam 81% of revenue (in H1 FY22) 100,000 Built-up area (sq. ft) from products manufactured at 345+ Products manufactured The Guwahati facility Capacity utili
Slide 16: Pan-India Sales Presence and Distribution Network
Pan-India Sales Presence and Distribution Network Stockists Region-wise sales distribution (H1 FY22) 11 Super Stockists 1 7 81 South , 39% 26 44 58 East, 10% 122 207 49 59 2 3 91 28 145 131 34 97 159 127 5 North , 22% 165 West, 29% 101 2 Central Warehouses 244 23 Sales Depots 137 2,133 Stockists 5,0
Slide 17: Board of Directors
Board of Directors • Eight-member Board of Directors, comprising of four Executive Directors and four Independent Directors, Amit Bakshi Krishnakumar V Inderjit Singh Negi Kaushal Shah including two women Chairman and Executive Director & directors Executive Director Executive Director Managing Dire
Slide 18: Lifestyle Diseases Uptrend – A Large Market Opportunity
Lifestyle Diseases Uptrend – A Large Market Opportunity Expected prevalence of CVD in India § Significant increase in prevalence of non- 69 communicable diseases (NCDs) in India; share of heart disease and metabolic disorders projected to expand in the years to come 29 22 19 6 8 § India is called th
Slide 19: Enduring Pillars of Our Business Strategy
Hence the Enduring Pillars of Our Business Strategy DOMESTIC BRANDED NS FORMULATIO CHRONIC AND SUB-CHRONIC THERAPIES SPECIALISTS AND CONSULTING PHYSICIANS 18
Slide 20: Key Growth Drivers (1/2)
Key Growth Drivers (1/2) Expansion of • Our business model of building strong and sustainable brands has enabled us to 1 power- maintain our growth trajectory during pandemic periods (Wave 1 as well as Wave 2) when brands’ MR-Doctor interactions were severely constrained franchise • There has been a
Slide 21: Key Growth Drivers (2/2)
Key Growth Drivers (2/2) Expansion of • We are working on significantly expanding our coverage of Specialists and Consulting 3 physician Physicians over the next 5 years coverage Therapeutic • We are investing in diversification opportunities in high-growth areas like neurology, 4 diversification wo
Slide 22: Safe Harbour Statement
Safe Harbour Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and the underlying assumptions
Slide 23: Eris Lifesciences Ltd.
Eris Lifesciences Ltd. CORPORATE OFFICE: Commerce House, Near Shell Petrol Pump, 100 Feet Rd, Satelite, Prahlad Nagar, Ahmedabad, Gujarat 380015 CIN: L24232GJ2007PLC049867 Website : www.eris.co.in IR Contact Kruti Raval kruti@erislifesciences.com 22
Slide 24: Appendix
Appendix
Slide 25: Business Structure and Holdings
Business Structure and Holdings Eris Lifesciences Limited Promoters Aprica Healthcare Limited 9.9% Earlier known as UTH Public 52.7% Healthcare Limited Kinedex Healthcare 13.6% Private Limited FPI Eris Therapeutics Limited DIIs 23.3% Eris Healthcare Private Limited Promoter shares are unencumbered E
Slide 26: Financial Summary (1/2)
Financial Summary (1/2) P&L Summary FY17 FY18 FY19 FY20 FY21 H1 FY22 Revenue 7,495 8,556 9,822 10,741 12,119 7,089 Gross Profit 6,449 7,215 8,285 9,025 9,736 5,737 Gross Profit Margin (%) 86.0% 84.3% 84.4% 84.0% 80.3% 80.9% Operating EBITDA 2,691 3,220 3,449 3,684 4,306 2,663 Operating EBITDA Margin
Slide 27: Financial Summary (2/2)
Financial Summary (2/2) FY17 FY18 FY19 FY20 FY21 H1 FY22 BS Summary Mar'17 Mar'18 Mar'19 Mar'20 Mar'21 H1 FY22 Margin (%) Share Capital 138 138 138 136 136 136 Gross Margin 86.0% 84.3% 84.4% 84.0% 80.3% 80.9% Reserves 5,534 8,476 11,368 12,828 15,628 17,120 EBITDA Margin 35.9% 37.6% 35.1% 34.3% 35.5
Slide 28: Key Brands in Oral Diabetes Care
Key Brands in Oral Diabetes Care Therapy wide presence in Oral Diabetes Care with power brands holding high ranks in newer generation fast-growing molecules (DPP4 and SGLT2 inhibitors) Sulfonylurea rank 6 in the ~4,700 cr Glimepiride and combinations market Glimisave MV rank 2 in Glimeperide + Vogli
Slide 29: Key Brands in Cardiovascular and VMN Therapies
Key Brands in Cardiovascular and VMN Therapies High rank in Anti-Hypertensives: the largest segment of Cardiac Care rank 5 in the ~3,700 cr Telmisartan and combinations market Eritel CH rank 4 in the Telmisartan + Chlorthalidone market Eritel LN rank 2 in the Telmisartan + Cilnidipine market rank 5
Slide 30: Thank You
Eris THANK YOU Eris Lifesciences
Eris Lifesciences — Investor Presentation (October 2021) on 6ix